FOI 25-0162 LD – Correspondence Regarding Me/cfs Recommendations

Written by Claude Haiku 4.5 from the extracted text on 27 Feb 2026. It can miss or misread redacted and scanned pages. Check the source before relying on it.

This FOI release comprises correspondence between Griffith University researchers and Department of Health officials regarding myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID research developments. The emails document discussions about Best Practice Guidelines for ME/CFS and research findings on TRPM3 ion channel pathology as an underlying mechanism in ME/CFS and Long COVID, with low-dose naltrexone (LDN) identified as a potential therapeutic intervention. The correspondence references independent German research validation of these findings and mentions publications on illness presentation and quality of life in ME/CFS and post-COVID-19 patients. The documents also reference pending communication from the U.S. National Academies of Science, Engineering and Medicine. The release shows Department engagement with academic research institutions on emerging disease mechanisms and potential treatment approaches for these conditions.